ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,041 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustrySchlierenMemo Therapeutics AG
Memo Therapeutics AG Logo
Verified· 3 sources

Memo Therapeutics AG

Summary

About the company

Memo Therapeutics AG develops therapeutic antibodies based on natural immune responses, with a focus on viral infections and cancer. Its main program is potravitug for BK polyomavirus infection in kidney transplant recipients, supported by the DROPZYLLA® platform for antibody discovery.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
✓ Offered
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4
Therapeutic Antibody Development
Therapeutic antibodies for viral infections, focused on BK polyomavirus in kidney transplant recipients; development of potravitug as lead program and antibody discovery with DROPZYLLA®.
BK Polyomavirus Therapy (Potravitug)
Monoclonal antibody for BK polyomavirus infections in kidney transplant recipients; in Phase II development, following a Phase I study in healthy volunteers with assessed safety and pharmacokinetics.
Clinical Development and Trials
Clinical development of antibody therapies with Phase I and Phase II studies, including a randomized, placebo-controlled trial with 90 patients in the USA.
Research Collaborations in Antibody Discovery
Research and development collaborations with pharma and research partners, including antibody discovery for oncology targets and support for the BKPyV program.
Press

Media

July 1, 2026Media
Ipsen to acquire Memo Therapeutics for up to EUR 700 million
startupticker.ch
July 1, 2026Media
Memo Therapeutics stellt neue Ergebnisse für Nierenstudie vor
punkt4.info
July 1, 2026Media
Ipsen kauft Memo Therapeutics AG
punkt4.info
February 10, 2026Media
Memo erhält für Kooperation mit CSL bis zu 265 Millionen Franken
punkt4.info
February 9, 2026Media
Memo Therapeutics enters into a collaboration with CSL
startupticker.ch
Comparisons

Memo Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Memo Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Memo Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Wagistrasse 27
8952 Schlieren

At a glance

Legal form
Corporation
UID
CHE-428.742.263
Founded
2019 · 7 years
Last commercial register change
August 7, 2026
Employees
21 to 50

Knowledge

No knowledge articles yet

Once Memo Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

MA
Mabylon AG
Schlieren
RA
Redbiotec AG
Schlieren
NT
NovaGo Therapeutics AG
Schlieren
LT
Linkster Therapeutics AG
Zurich
TP
Takeda Pharmaceuticals International AG
Glattpark (Opfikon)
FH
Future Health Pharma GmbH
Wetzikon Zh 1
EA
Evax AG
Zurich
SA
Stallergenes AG
Dietlikon